Sugi Predict

Sugi Predict / Compounds / SCHEMBL413795

SCHEMBL413795

SCHEMBL413795

COCNC(=O)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.55
▸ PTPN2 P17706 1/20 0.54
▸ PTPN1 P18031 1/20 0.54
▸ PTPN6 P29350 1/20 0.54
▸ RECQL P46063 1/20 0.52
▸ EPHX2 P34913 1/20 0.52
▸ STS P08842 8/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ EPHX1 P07099 1/20 0.49
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ABL1 P00519 1/20 0.47
▸ RIN1 Q13671 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3730648 0.95 HPGD (0.50) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL389961 0.93 HPGD (0.51) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL1155860 0.93 HPGD (0.51) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL1156346 0.93 HPGD (0.51) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL1309545 0.87 NR1H2 (0.47) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL30230001 0.86 MAPT (0.54) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL15049749 0.85 MEN1 (0.57) HPGDKMT2AEPHX1ABL1RIN1
SCHEMBL442931 0.85 MEN1 (0.57) HPGDKMT2AEPHX1ABL1RIN1
SCHEMBL18768415 0.85 HPGD (0.57) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL1440590 0.83 GAA (0.53) HPGDPTPN2PTPN1PTPN6RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105777668-A Synthesis method of medicine intermediate 1-tert-butyloxycarbonyl-4-(methoxy-methyl-carbamoyl)piperidine 无锡乾浩生物医药有限公司 2016-07-20 — — CN claimed
CN-115850241-B Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof 中国药科大学 2025-01-14 — — CN disclosed
US-20240391901-A1 SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2024-11-28 — — US disclosed
WO-2024042480-A1 HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SUVEN LIFE SCIENCES LIMITED (IN) 2024-02-29 — — WO disclosed
WO-2023046055-A1 SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING α-KETONE FRAMEWORK, AND USE THEREOF 中国药科大学 2023-03-30 — — WO disclosed
CN-115850241-A Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof 中国药科大学 2023-03-28 — — CN disclosed
CN-108137556-B 1, 4-dicarbonyl-piperidinyl derivatives 默克专利股份公司 2021-07-30 — — CN disclosed
US-10570116-B2 1,4-dicarbonyl-piperidyl derivatives MERCK PATENT GMBH (DE) 2020-02-25 — — US disclosed
EP-3371166-B1 1,4-DICARBONYL-PIPERIDYL DERIVATIVES MERCK PATENT GMBH (DE) 2019-11-20 — — EP disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
WO-2002066468-A2 HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS AVENTIS PHARMACEUTICALS INC. (US) 2002-08-29 — — WO disclosed
WO-2002066469-A2 NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS AVENTIS PHARMACEUTICALS INC. (US) 2002-08-29 — — WO disclosed
WO-2002066446-A1 HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS AVENTIS PHARMACEUTICALS INC. (US) 2002-08-29 — — WO disclosed
US-20020068753-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. 2002-06-06 — — US disclosed
US-20020045613-A1 1-aroyl-piperidinyl benzamidines AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-04-18 — — US disclosed
WO-2002020483-A1 PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-03-14 — — WO disclosed
WO-2001081310-A1 1-AROYL-PIPERIDINYL BENZAMIDINES AVENTIS PHARMACEUTICALS INC. (US) 2001-11-01 — — WO disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 — — US disclosed
US-5717100-A Substituted imidazoles having anti-cancer and cytokine inhibitory activity MERCK & CO., INC. (US) 1998-02-10 — — US disclosed
WO-1997012876-A9 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY — 1997-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570116-B2 1,4-dicarbonyl-piperidyl derivatives TNKS, TANK, TBKBP1 HPGD 2753/4885PTPN2 1623/4885PTPN1 932/4885
US-20020045613-A1 1-aroyl-piperidinyl benzamidines TPSAB1, TPSB2, CMA1 HPGD 931/4885PTPN2 3871/4885PTPN1 3045/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 HPGD 75/4885PTPN2 1073/4885PTPN1 1325/4885
US-20020068753-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 HPGD 43/4885PTPN2 3841/4885PTPN1 3782/4885
US-20240391901-A1 SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF FAAH, FAAH2, FAH HPGD 528/4885PTPN2 3257/4885PTPN1 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.